fbpx

ADVERTISEMENT

ADVERTISEMENT

Pheochromocytoma

Updated : September 6, 2023





Background

Pheochromocytoma (Chromaffin Cell Cancer) is a tumor that can produce hormones and develop in the adrenal glands. Mr. Pick coined the word “pheochromocytoma” in 1912. Chromaffin cells found in the adrenal medulla and paraganglion cells can develop into a tumor called a pheochromocytoma.

It was given this name because these tissues respond differently when chromium salt is applied to them. In 1937, Dr. Charles Mayo published the first pheochromocytoma case, which included a medical assessment and a surgical excision for therapeutic purposes.

Epidemiology

A very uncommon neuroendocrine condition is pheochromocytoma. It affects between 0.05 percent and 0.2 percent of people with hypertension. It is detected in roughly two to eight people out of 1 million people in the US, with a yearly incidence of 0.8 every 100,000 individuals’-years.

Both genders are equally affected by it. Pheochromocytoma is often diagnosed between the ages of 30 and 50, but it might manifest sooner due to hereditary susceptibility.

Anatomy

Pathophysiology

A neuroendocrine neoplasm that secretes catecholamines is called a pheochromocytoma. It belongs to one of the three catecholamine-secreting kinds.

Tumors produce just norepinephrine and are typically associated with persistent hypertension. Paroxysmal hypertension is a presenting symptom of tumors that secrete norepinephrine and epinephrine. Hypotension, as opposed to hypertension, can only be brought on by epinephrine.

The inotropic impact, systemic vascular resistance, heart rate, and decrease in venous compliance all rise as a result of catecholamine secretion. Postural hypotension occurs in pheochromocytoma because it is a volume-depletion form of hypertension.

Etiology

90 percent of the time, pheochromocytoma is sporadic; however, in 10 percent of cases, it is hereditary and linked to disorders including Von Hippel-Lindau syndrome, multiple endocrine neoplasm syndromes type IIA and IIB, and neurofibromatosis type 1 with an autosomal dominant transmission mechanism.

Genetics

Prognostic Factors

Surgery typically cures non-metastatic cancers or benign ones. 50 percent of metastatic cancers survive for five years.

Clinical History

Physical Examination

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

 

metyrosine 

Starting dose of 250 mg taken orally every six hours and increase by 250 to 500 mg/day, but not exceeding a maximum of 4 g/day
Maintenance dose of usually 2 to 3 g/day, divided into four equal doses every six hours
Dosing Considerations Not advised in hypertension



iobenguane I-123 

Gamma Scintigraphy
Administer dose of 10 millicurie intravenously
Begin whole body planar scintigraphy imaging 24 hours (plus or minus 6 hours) after administration



 

olsalazine 

For <12 years: Safety and efficacy not determined
For ≥12 years
Starting dose of 250 mg taken orally every six hours and increase by 250 to 500 mg/day, but not exceeding a maximum of 4 g/day
Maintenance dose of usually 2 to 3 g/day, divided into four equal doses every six hours
Dosing Considerations Not advised in hypertension



iobenguane I-123 

Gamma Scintigraphy
Start full body planar scintigraphy imaging 24 hours (plus or minus 6 hours) after administration



 

Media Gallary

References

https://www.ncbi.nlm.nih.gov/books/NBK535360/

ADVERTISEMENT 

Pheochromocytoma

Updated : September 6, 2023




Pheochromocytoma (Chromaffin Cell Cancer) is a tumor that can produce hormones and develop in the adrenal glands. Mr. Pick coined the word “pheochromocytoma” in 1912. Chromaffin cells found in the adrenal medulla and paraganglion cells can develop into a tumor called a pheochromocytoma.

It was given this name because these tissues respond differently when chromium salt is applied to them. In 1937, Dr. Charles Mayo published the first pheochromocytoma case, which included a medical assessment and a surgical excision for therapeutic purposes.

A very uncommon neuroendocrine condition is pheochromocytoma. It affects between 0.05 percent and 0.2 percent of people with hypertension. It is detected in roughly two to eight people out of 1 million people in the US, with a yearly incidence of 0.8 every 100,000 individuals’-years.

Both genders are equally affected by it. Pheochromocytoma is often diagnosed between the ages of 30 and 50, but it might manifest sooner due to hereditary susceptibility.

A neuroendocrine neoplasm that secretes catecholamines is called a pheochromocytoma. It belongs to one of the three catecholamine-secreting kinds.

Tumors produce just norepinephrine and are typically associated with persistent hypertension. Paroxysmal hypertension is a presenting symptom of tumors that secrete norepinephrine and epinephrine. Hypotension, as opposed to hypertension, can only be brought on by epinephrine.

The inotropic impact, systemic vascular resistance, heart rate, and decrease in venous compliance all rise as a result of catecholamine secretion. Postural hypotension occurs in pheochromocytoma because it is a volume-depletion form of hypertension.

90 percent of the time, pheochromocytoma is sporadic; however, in 10 percent of cases, it is hereditary and linked to disorders including Von Hippel-Lindau syndrome, multiple endocrine neoplasm syndromes type IIA and IIB, and neurofibromatosis type 1 with an autosomal dominant transmission mechanism.

Surgery typically cures non-metastatic cancers or benign ones. 50 percent of metastatic cancers survive for five years.

metyrosine 

Starting dose of 250 mg taken orally every six hours and increase by 250 to 500 mg/day, but not exceeding a maximum of 4 g/day
Maintenance dose of usually 2 to 3 g/day, divided into four equal doses every six hours
Dosing Considerations Not advised in hypertension



iobenguane I-123 

Gamma Scintigraphy
Administer dose of 10 millicurie intravenously
Begin whole body planar scintigraphy imaging 24 hours (plus or minus 6 hours) after administration



olsalazine 

For <12 years: Safety and efficacy not determined
For ≥12 years
Starting dose of 250 mg taken orally every six hours and increase by 250 to 500 mg/day, but not exceeding a maximum of 4 g/day
Maintenance dose of usually 2 to 3 g/day, divided into four equal doses every six hours
Dosing Considerations Not advised in hypertension



iobenguane I-123 

Gamma Scintigraphy
Start full body planar scintigraphy imaging 24 hours (plus or minus 6 hours) after administration



https://www.ncbi.nlm.nih.gov/books/NBK535360/

Free CME credits

Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.

Digital Certificate PDF

On course completion, you will receive a full-sized presentation quality digital certificate.

medtigo Simulation

A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.

medtigo Points

medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
 
  • Registration with medtigo = 10 points
  • 1 visit to medtigo’s website = 1 point
  • Interacting with medtigo posts (through comments/clinical cases etc.) = 5 points
  • Attempting a game = 1 point
  • Community Forum post/reply = 5 points

    *Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.

All Your Certificates in One Place

When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.

Our Certificate Courses